Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Compass Therapeutics, Inc. (CMPX)
USD2.14
-0.06 (-2.51%)
US NASDAQ Healthcare Biotechnology
Address
80 Guest Street 2135
Boston, MA, US
Boston, MA, US
CEO
Thomas J. Schuetz
Website
compasstherapeutics.com
IPO
2021-04-05
CIK 1738021 ISIN US20454B1044
Description
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.14
-0.06 (-2.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.74
Float Shares
97.03M
Free Float %
70.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.24% | +16.67% | +34.46% | -57.88% | -58.97% | -55.68% | +13.33% | -15.30% | -47.11% | -72.00% | -72.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (15 ratings, all time)
Buy
Price Targets & DCF
Current price
2.14
Low
9.00
+321.5%
Consensus
11.20
+424.6%
Median
10.00
+368.4%
High
15.00
+602.6%
DCF (Unlevered)
0.12
-94.3%
DCF (Levered)
0.13
-93.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
93% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | -1 |
| Buy | 12 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
9.00
+321.5%
|
| Last Year | 6 |
11.00
+415.2%
|
| All Time | 8 |
9.63
+351.1%
|
Quality scores
Altman Z-Score
6.02
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-16.7% Q1'26: +16.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -5,148.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+15.0% Q1'26: +34.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.14× Q1'26: -0.12× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 11 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 12 Rev. Ana. 12 EPS Ana. |
Dec 2029 11 Rev. Ana. 10 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 850.0K (-100.0%)
|
850.0K
est: 888.9K (-4.4%)
|
—
est: 4.66M (-100.0%)
|
-2.40M
-4.84M – -978.5K
-151.5% YoY
|
25.90M
2.93M – 71.80M
+1,179.1% YoY
|
126.88M
126.88M – 126.88M
+389.9% YoY
|
264.29M
107.75M – 533.39M
+108.3% YoY
|
377.97M
154.10M – 762.83M
+43.0% YoY
|
| EBITDA |
-48.47M
est: 510.0K (-9,604.5%)
|
-54.87M
est: 533.3K (-10,388.5%)
|
-71.37M
est: 2.80M (-2,651.1%)
|
-1.44M
-2.91M – -587.1K
-151.5% YoY
|
15.54M
1.76M – 43.08M
+1,179.1% YoY
|
76.13M
76.13M – 76.13M
+389.9% YoY
|
158.57M
64.65M – 320.03M
+108.3% YoY
|
226.78M
92.46M – 457.70M
+43.0% YoY
|
| EBIT |
-50.36M
est: 510.0K (-9,975.1%)
|
-56.63M
est: 533.3K (-10,717.2%)
|
-72.84M
est: 2.80M (-2,703.7%)
|
-1.44M
-2.91M – -587.1K
-151.5% YoY
|
15.54M
1.76M – 43.08M
+1,179.1% YoY
|
76.13M
76.13M – 76.13M
+389.9% YoY
|
158.57M
64.65M – 320.03M
+108.3% YoY
|
226.78M
92.46M – 457.70M
+43.0% YoY
|
| Net Income |
-42.49M
est: -47.24M (+10.1%)
|
-49.38M
est: -62.03M (+20.4%)
|
-66.49M
est: -68.17M (+2.5%)
|
-82.94M
-97.29M – -51.79M
-21.7% YoY
|
-89.49M
-110.30M – -35.68M
-7.9% YoY
|
-28.00M
-105.66M – 50.46M
+68.7% YoY
|
47.16M
10.85M – 109.60M
+268.4% YoY
|
103.61M
23.83M – 240.75M
+119.7% YoY
|
| SGA |
12.24M
est: 3.71M (+230.3%)
|
15.13M
est: 3.88M (+290.4%)
|
16.87M
est: 20.33M (-17.0%)
|
-10.47M
-21.12M – -4.27M
-151.5% YoY
|
112.94M
12.78M – 313.11M
+1,179.1% YoY
|
553.30M
553.30M – 553.30M
+389.9% YoY
|
1.15B
469.86M – 2.33B
+108.3% YoY
|
1.65B
671.97M – 3.33B
+43.0% YoY
|
| EPS |
-0.33
est: -0.36 (+7.6%)
|
-0.36
est: -0.35 (-2.6%)
|
-0.42
est: -0.43 (+2.6%)
|
-0.44
-0.62 – -0.33
-1.6% YoY
|
-0.46
-0.70 – -0.23
-5.7% YoY
|
-0.14
-0.67 – 0.32
+69.0% YoY
|
0.30
0.07 – 0.70
+308.7% YoY
|
0.66
0.15 – 1.53
+119.7% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-28 | Canaccord Genuity | Buy | Buy | Maintain |
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-87.91M
OE per share TTM
-0.58
Owner's Yield
-19.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4,083.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
208
Total invested
919.10M
Insider transactions (90d)
2
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blackstone Group Management L.L.C. | 9.50M | 6.90% | — | 9.50M | — | 9.50M | OO | Cayman Islands | 2024-08-02 | ↗ |
| 2 | Blackstone Inc. | 9.50M | 6.90% | — | 9.50M | — | 9.50M | CO | Cayman Islands | 2024-08-02 | ↗ |
| 3 | Stephen A. Schwarzman | 9.50M | 6.90% | — | 9.50M | — | 9.50M | IN | Cayman Islands | 2024-08-02 | ↗ |
| 4 | Blackstone Alternative Asset Management Associates LLC | 7.99M | 5.80% | — | 7.99M | — | 7.99M | OO | Cayman Islands | 2024-08-02 | ↗ |
| 5 | Blackstone Holdings I/II GP L.L.C. | 7.99M | 5.80% | — | 7.99M | — | 7.99M | OO | Cayman Islands | 2024-08-02 | ↗ |
| 6 | Blackstone Holdings II L.P. | 7.99M | 5.80% | — | 7.99M | — | 7.99M | PN | Cayman Islands | 2024-08-02 | ↗ |
| 7 | EIN #00-0000000 | 7.65M | 6.00% | — | 7.65M | — | 7.65M | IA, HC | Jersey, Channel Islands | 2024-02-01 | ↗ |
| 8 | Adage Capital Management, L.P. | 7.21M | 5.66% | — | 7.21M | — | — | IA, PN | Delaware | 2023-11-27 | ↗ |
| 9 | Adage Capital Partners GP, L.L.C. | 7.21M | 5.66% | — | 7.21M | — | — | OO | Delaware | 2023-11-27 | ↗ |
| 10 | Adage Capital Partners, L.P. | 7.21M | 5.66% | — | 7.21M | — | — | PN | Delaware | 2023-11-27 | ↗ |
| 11 | Phillip Gross | 7.21M | 5.66% | — | 7.21M | — | — | IN | United States | 2023-11-27 | ↗ |
| 12 | Robert Atchinson | 7.21M | 5.66% | — | 7.21M | — | — | IN | Delaware | 2023-11-27 | ↗ |
| 13 | 00-0000000 | 6.94M | 5.40% | — | 6.94M | — | 6.94M | CO | Cayman Islands | 2024-02-01 | ↗ |
| 14 | B. Tananbaum (“Tananbaum”) | 5.50M | 5.60% | 5.50M | — | 5.50M | — | IN | Delaware | 2021-11-12 | ↗ |
| 15 | Rock Springs Capital LLC | 5.33M | 5.44% | — | 5.33M | — | — | HC, OO | — | 2022-02-15 | ↗ |
| 16 | Rock Springs Capital Management LP | 5.33M | 5.44% | — | 5.33M | — | — | IA | Delaware | 2022-02-15 | ↗ |
| 17 | Rock Springs Capital Master Fund LP | 4.93M | 5.02% | — | 4.93M | — | — | PN | — | 2022-02-15 | ↗ |
| 18 | Capital Fund V, L.P. (“FCF V”) | 4.40M | 4.50% | 4.40M | — | 4.40M | — | PN | Delaware | 2021-11-12 | ↗ |
| 19 | Capital Management V, LLC (“FCM V”) | 4.40M | 4.50% | 4.40M | — | 4.40M | — | OO | Delaware | 2021-11-12 | ↗ |
| 20 | Spruce Street Aggregator L.P. | 4.38M | 3.20% | — | 4.38M | — | 4.38M | PN | Cayman Islands | 2024-08-02 | ↗ |
| 21 | Blackstone Annex Master Fund L.P. | 3.61M | 2.60% | — | 3.61M | — | 3.61M | PN | Cayman Islands | 2024-08-02 | ↗ |
| 22 | Capital Opportunity Fund V, L.P. (“FCF Opp V”) | 1.10M | 1.10% | 1.10M | — | 1.10M | — | PN | Delaware | 2021-11-12 | ↗ |
| 23 | Capital Opportunity Management V, LLC (“FCM Opp V”) | 1.10M | 1.10% | 1.10M | — | 1.10M | — | OO | Delaware | 2021-11-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
208
+36 vs prev Q
New positions
53
Closed positions
23
Increased
126
Reduced
49
Put/Call ratio
0.06
Calls held
3.31M
Puts held
188.9K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.11M +1.1M (+100.0%) | 5.98B +6.0B (+100.0%) | 0.81% +0.806 pp | 3.51% +3.509 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 2 | TANG CAPITAL MANAGEMENT LLC | 16.79M -21.2K (-0.1%) | 90.17M +31.3M (+53.2%) | 12.14% -0.015 pp | 4.45% +2.189 pp | USD2.20 +144.1% | 6 qtrs — |
| 3 | ORBIMED ADVISORS LLC | 15.22M +— (+0.0%) | 81.73M +28.5M (+53.4%) | 11.01% +0.000 pp | 1.68% +0.420 pp | USD3.20 +67.8% | 17 qtrs — |
| 4 | SUVRETTA CAPITAL MANAGEMENT, LLC | 14.18M +81.2K (+0.6%) | 76.16M +26.8M (+54.3%) | 10.26% +0.059 pp | 1.56% +0.297 pp | USD3.06 +75.5% | 3 qtrs — |
| 5 | VIVO CAPITAL, LLC | 9.55M +— (+0.0%) | 51.26M +17.9M (+53.4%) | 6.90% +0.000 pp | 3.31% +0.625 pp | USD3.45 +55.7% | 17 qtrs — |
| 6 | BLACKROCK, INC. | 9.39M +2.0M (+27.4%) | 50.42M +24.6M (+95.4%) | 6.79% +1.459 pp | 0.00% +0.000 pp | USD2.77 +93.9% | 6 qtrs — |
| 7 | VANGUARD GROUP INC | 8.05M +985.6K (+14.0%) | 43.22M +18.5M (+74.8%) | 5.82% +0.713 pp | 0.00% +0.000 pp | USD3.57 +50.4% | 17 qtrs — |
| 8 | ENAVATE SCIENCES GP, LLC | 7.79M +— (+0.0%) | 41.82M +14.6M (+53.4%) | 5.63% +0.000 pp | 8.25% -0.070 pp | USD1.45 +270.3% | 5 qtrs — |
| 9 | BVF INC/IL | 7.76M +3.0M (+63.5%) | 41.70M +25.1M (+150.8%) | 5.62% +2.180 pp | 1.40% +0.730 pp | USD4.23 +27.0% | 2 qtrs — |
| 10 | BLACKSTONE INC. | 6.13M -3.7M (-37.7%) | 32.90M -1.5M (-4.5%) | 4.43% -2.686 pp | 0.13% -0.009 pp | USD3.08 +74.4% | 17 qtrs — |
| 11 | STATE STREET CORP | 4.89M +1.8M (+57.4%) | 26.26M +15.4M (+141.5%) | 3.54% +1.290 pp | 0.00% +0.001 pp | USD4.08 +31.6% | 13 qtrs — |
| 12 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.44M -750.0K (-14.5%) | 23.82M +5.7M (+31.2%) | 3.21% -0.542 pp | 0.04% +0.007 pp | USD2.61 +105.7% | 17 qtrs — |
| 13 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.93M -547.5K (-12.2%) | 21.09M +5.4M (+34.7%) | 2.84% -0.396 pp | 1.08% +0.166 pp | USD3.10 +73.2% | 17 qtrs — |
| 14 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3.61M +3.6M (+100.0%) | 19.36M +19.4M (+100.0%) | 2.61% +2.608 pp | 0.25% +0.247 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 3.50M +558.1K (+19.0%) | 18.81M +8.5M (+82.5%) | 2.53% +0.404 pp | 0.00% +0.001 pp | USD3.26 +64.7% | 16 qtrs — |
| 16 | BLUE OWL CAPITAL HOLDINGS LP | 3.47M +875.0K (+33.8%) | 18.62M +9.5M (+105.2%) | 2.51% +0.633 pp | 1.39% -1.423 pp | USD2.52 +113.1% | 9 qtrs — |
| 17 | SOFINNOVA INVESTMENTS, INC. | 3.37M +1.3M (+65.9%) | 18.07M +11.0M (+154.5%) | 2.43% +0.967 pp | 0.78% +0.391 pp | USD4.24 +26.7% | 2 qtrs — |
| 18 | MILLENNIUM MANAGEMENT LLC | 3.11M -128.3K (-4.0%) | 16.70M +5.4M (+47.3%) | 2.25% -0.093 pp | 0.01% +0.002 pp | USD3.14 +71.0% | 17 qtrs — |
| 19 | BRAIDWELL LP | 2.79M +2.8M (+100.0%) | 14.96M +15.0M (+100.0%) | 2.02% +2.015 pp | 0.48% +0.479 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 20 | FMR LLC | 2.58M -1.6M (-37.7%) | 13.85M -628.4K (-4.3%) | 1.87% -1.127 pp | 0.00% +0.000 pp | USD3.17 +69.4% | 17 qtrs — |
| 21 | PALO ALTO INVESTORS LP | 2.53M +2.5M (+100.0%) | 13.60M +13.6M (+100.0%) | 1.83% +1.831 pp | 1.89% +1.893 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 22 | RTW INVESTMENTS, LP | 2.50M +— (+0.0%) | 13.43M +4.7M (+53.4%) | 1.81% +0.000 pp | 0.13% +0.027 pp | USD3.50 +53.4% | 2 qtrs — |
| 23 | BALYASNY ASSET MANAGEMENT L.P. | 1.59M -1.2M (-43.6%) | 8.56M -1.3M (-13.5%) | 1.15% -0.892 pp | 0.01% -0.002 pp | USD3.50 +53.4% | 2 qtrs — |
| 24 | BIRCHVIEW CAPITAL, LP | 1.59M +720.0K (+82.5%) | 8.55M +5.5M (+180.0%) | 1.15% +0.521 pp | 5.01% +2.702 pp | USD4.35 +23.4% | 4 qtrs — |
| 25 | GOLDMAN SACHS GROUP INC | 1.52M +477.7K (+46.0%) | 8.15M +4.5M (+123.9%) | 1.10% +0.346 pp | 0.00% +0.001 pp | USD3.96 +35.6% | 12 qtrs — |
| 26 | MARSHALL WACE, LLP | 1.26M +1.3M (+100.0%) | 6.79M +6.8M (+100.0%) | 0.91% +0.914 pp | 0.01% +0.006 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 27 | LOGOS GLOBAL MANAGEMENT LP | 1.15M -900.0K (-43.9%) | 6.18M -999.5K (-13.9%) | 0.83% -0.651 pp | 0.37% -0.270 pp | USD3.50 +53.4% | 2 qtrs — |
| 28 | ACUTA CAPITAL PARTNERS, LLC | 1.09M +253.2K (+30.1%) | 5.87M +2.9M (+99.7%) | 0.79% +0.183 pp | 3.99% +0.948 pp | USD3.93 +36.6% | 2 qtrs — |
| 29 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.05M -1.8M (-62.9%) | 5.65M -4.3M (-43.1%) | 0.76% -1.289 pp | 0.78% -0.553 pp | USD2.89 +85.8% | 4 qtrs — |
| 30 | MONASHEE INVESTMENT MANAGEMENT LLC | 1.00M -250.0K (-20.0%) | 5.37M +995.0K (+22.7%) | 0.72% -0.181 pp | 3.03% +0.844 pp | USD3.57 +50.4% | 17 qtrs — |
| 31 | NORTHERN TRUST CORP | 972.9K +111.0K (+12.9%) | 5.22M +2.2M (+73.2%) | 0.70% +0.080 pp | 0.00% +0.000 pp | USD3.33 +61.3% | 14 qtrs — |
| 32 | JPMORGAN CHASE & CO | 870.0K -1.1M (-56.5%) | 4.67M -2.3M (-33.2%) | 0.63% -0.817 pp | 0.00% 0.000 pp | USD1.87 +187.2% | 12 qtrs — |
| 33 | AMERIPRISE FINANCIAL INC | 823.2K +823.2K (+100.0%) | 4.42M +4.4M (+100.0%) | 0.60% +0.595 pp | 0.00% +0.001 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 34 | IKARIAN CAPITAL, LLC | 800.0K +800.0K (+100.0%) | 4.30M +4.3M (+100.0%) | 0.58% +0.579 pp | 0.34% +0.335 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 35 | BURKEHILL GLOBAL MANAGEMENT, LP | 700.0K +— (+0.0%) | 3.76M +1.3M (+53.4%) | 0.51% +0.000 pp | 0.25% +0.108 pp | USD3.50 +53.4% | 2 qtrs — |
| 36 | BARCLAYS PLC | 594.8K +424.5K (+249.4%) | 3.19M +2.9M (+919.6%) | 0.43% +0.307 pp | 0.00% +0.001 pp | USD4.48 +19.9% | 14 qtrs — |
| 37 | HEALTHINVEST PARTNERS AB | 584.3K +584.3K (+100.0%) | 3.14M +3.1M (+100.0%) | 0.42% +0.423 pp | 1.00% +1.001 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 38 | Y-INTERCEPT (HONG KONG) LTD | 462.2K +462.2K (+100.0%) | 2.48M +2.5M (+100.0%) | 0.33% +0.334 pp | 0.06% +0.056 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 39 | SCHONFELD STRATEGIC ADVISORS LLC | 452.4K -23.8K (-5.0%) | 2.43M +762.6K (+45.7%) | 0.33% -0.017 pp | 0.01% +0.001 pp | USD3.50 +53.4% | 2 qtrs — |
| 40 | QUBE RESEARCH & TECHNOLOGIES LTD | 441.8K +441.8K (+100.0%) | 2.37M +2.4M (+100.0%) | 0.32% +0.320 pp | 0.00% +0.002 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 41 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 410.2K +74.9K (+22.3%) | 2.20M +1.0M (+87.7%) | 0.30% +0.054 pp | 0.00% +0.000 pp | USD3.32 +61.7% | 14 qtrs — |
| 42 | MORGAN STANLEY | 365.2K +178.3K (+95.4%) | 1.96M +1.3M (+199.8%) | 0.26% +0.129 pp | 0.00% +0.000 pp | USD3.61 +48.8% | 17 qtrs — |
| 43 | DIMENSIONAL FUND ADVISORS LP | 341.6K +166.0K (+94.6%) | 1.83M +1.2M (+196.5%) | 0.25% +0.120 pp | 0.00% +0.000 pp | USD3.71 +44.7% | 11 qtrs — |
| 44 | WELLINGTON MANAGEMENT GROUP LLP | 316.8K -1.3K (-0.4%) | 1.70M +588.0K (+52.8%) | 0.23% -0.001 pp | 0.00% +0.000 pp | USD2.15 +149.8% | 4 qtrs — |
| 45 | PRUDENTIAL FINANCIAL INC | 314.8K +314.8K (+100.0%) | 1.69M +1.7M (+100.0%) | 0.23% +0.228 pp | 0.00% +0.002 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 46 | BANK OF NEW YORK MELLON CORP | 312.5K +89.3K (+40.0%) | 1.68M +896.9K (+114.8%) | 0.23% +0.065 pp | 0.00% +0.000 pp | USD3.62 +48.3% | 14 qtrs — |
| 47 | NUVEEN, LLC | 288.9K +29.7K (+11.5%) | 1.55M +644.3K (+71.0%) | 0.21% +0.022 pp | 0.00% +0.000 pp | USD2.26 +137.6% | 4 qtrs — |
| 48 | ROYCE & ASSOCIATES LP | 286.0K +286.0K (+100.0%) | 1.54M +1.5M (+100.0%) | 0.21% +0.207 pp | 0.02% +0.016 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 49 | BANK OF AMERICA CORP /DE/ | 266.4K +192.6K (+261.0%) | 1.43M +1.2M (+453.9%) | 0.19% +0.139 pp | 0.00% +0.000 pp | USD4.66 +15.2% | 13 qtrs — |
| 50 | CITIGROUP INC | 261.9K +251.2K (+2,358.7%) | 1.41M +1.4M (+3,672.3%) | 0.19% +0.182 pp | 0.00% +0.001 pp | USD5.22 +2.9% | 17 qtrs — |
| 51 | HIGHVISTA STRATEGIES LLC | 245.5K +245.5K (+100.0%) | 1.32M +1.3M (+100.0%) | 0.18% +0.178 pp | 0.34% +0.340 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 52 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 210.2K +210.2K (+100.0%) | 1.13M +1.1M (+100.0%) | 0.15% +0.152 pp | 0.00% +0.001 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 53 | BOOTHBAY FUND MANAGEMENT, LLC | 205.0K +205.0K (+100.0%) | 1.10M +1.1M (+100.0%) | 0.15% +0.148 pp | 0.02% +0.016 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 54 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 191.7K +191.7K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.14% +0.139 pp | 0.00% +0.003 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 55 | STATE OF WISCONSIN INVESTMENT BOARD | 185.4K +144.0K (+347.9%) | 995.7K +850.8K (+587.2%) | 0.13% +0.104 pp | 0.00% +0.002 pp | USD4.95 +8.5% | 4 qtrs — |
| 56 | UBS GROUP AG | 167.9K -30.4K (-15.3%) | 901.4K +207.4K (+29.9%) | 0.12% -0.022 pp | 0.00% +0.000 pp | USD2.14 +150.9% | 17 qtrs — |
| 57 | AQR CAPITAL MANAGEMENT LLC | 155.2K +96.1K (+162.4%) | 833.5K +626.5K (+302.6%) | 0.11% +0.070 pp | 0.00% +0.000 pp | USD4.38 +22.6% | 3 qtrs — |
| 58 | RAFFERTY ASSET MANAGEMENT, LLC | 151.7K +80.8K (+113.8%) | 814.9K +566.5K (+228.1%) | 0.11% +0.058 pp | 0.00% +0.002 pp | USD4.50 +19.3% | 2 qtrs — |
| 59 | ALPS ADVISORS INC | 146.0K +63.0K (+75.9%) | 784.2K +493.7K (+169.9%) | 0.11% +0.046 pp | 0.00% +0.003 pp | USD3.85 +39.5% | 3 qtrs — |
| 60 | WELLS FARGO & COMPANY/MN | 144.8K +76.6K (+112.4%) | 777.6K +539.0K (+225.9%) | 0.10% +0.055 pp | 0.00% +0.000 pp | USD3.95 +35.9% | 14 qtrs — |
| 61 | ADAR1 CAPITAL MANAGEMENT, LLC | 139.0K +89.0K (+178.0%) | 746.4K +571.4K (+326.5%) | 0.10% +0.064 pp | 0.05% +0.038 pp | USD4.54 +18.3% | 3 qtrs — |
| 62 | RHUMBLINE ADVISERS | 134.6K -4.7K (-3.4%) | 722.8K +235.2K (+48.2%) | 0.10% -0.003 pp | 0.00% +0.000 pp | USD2.97 +80.8% | 11 qtrs — |
| 63 | GSA CAPITAL PARTNERS LLP | 133.8K +133.8K (+100.0%) | 719.0K +719.0K (+100.0%) | 0.10% +0.097 pp | 0.06% +0.062 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 64 | SQUAREPOINT OPS LLC | 126.2K +38.3K (+43.6%) | 677.7K +370.2K (+120.4%) | 0.09% +0.028 pp | 0.00% +0.000 pp | USD3.92 +37.0% | 9 qtrs — |
| 65 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 118.5K +72.7K (+158.4%) | 636.5K +475.9K (+296.4%) | 0.09% +0.053 pp | 0.01% +0.006 pp | USD4.65 +15.5% | 2 qtrs — |
| 66 | XTX TOPCO LTD | 115.6K +98.7K (+582.2%) | 621.0K +561.6K (+946.7%) | 0.08% +0.071 pp | 0.02% +0.013 pp | USD4.96 +8.3% | 6 qtrs — |
| 67 | DEUTSCHE BANK AG\ | 109.3K +13.5K (+14.1%) | 586.8K +251.5K (+75.0%) | 0.08% +0.010 pp | 0.00% +0.000 pp | USD2.50 +114.8% | 11 qtrs — |
| 68 | CREATIVE PLANNING | 108.1K +47.2K (+77.5%) | 580.7K +367.5K (+172.3%) | 0.08% +0.034 pp | 0.00% +0.000 pp | USD4.22 +27.3% | 3 qtrs — |
| 69 | SG AMERICAS SECURITIES, LLC | 106.5K -42.8K (-28.7%) | 572.0K +49.0K (+9.4%) | 0.08% -0.031 pp | 0.00% -0.001 pp | USD1.72 +212.2% | 10 qtrs — |
| 70 | CITADEL ADVISORS LLC | 105.7K -127.6K (-54.7%) | 567.5K -248.9K (-30.5%) | 0.08% -0.092 pp | 0.00% +0.000 pp | USD3.50 +53.4% | 2 qtrs — |
| 71 | NEOS INVESTMENT MANAGEMENT LLC | 101.7K +101.7K (+100.0%) | 546.0K +546.0K (+100.0%) | 0.07% +0.074 pp | 0.00% +0.003 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 72 | TEMA ETFS LLC | 100.2K +100.2K (+100.0%) | 537.9K +537.9K (+100.0%) | 0.07% +0.072 pp | 0.04% +0.042 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 73 | CM MANAGEMENT, LLC | 100.0K -50.0K (-33.3%) | 537.0K +12.0K (+2.3%) | 0.07% -0.036 pp | 0.45% +0.015 pp | USD3.50 +53.4% | 2 qtrs — |
| 74 | ALLIANCEBERNSTEIN L.P. | 83.9K -20.2K (-19.4%) | 450.8K +86.2K (+23.6%) | 0.06% -0.015 pp | 0.00% +0.000 pp | USD2.50 +114.8% | 11 qtrs — |
| 75 | SUMMITTX CAPITAL, L.P. | 81.4K +81.4K (+100.0%) | 437.4K +437.4K (+100.0%) | 0.06% +0.059 pp | 0.01% +0.013 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 76 | RAYMOND JAMES FINANCIAL INC | 80.1K +80.1K (+100.0%) | 430.4K +430.4K (+100.0%) | 0.06% +0.058 pp | 0.00% +0.000 pp | USD5.37 +0.0% | 3 qtrs — |
| 77 | ATOM INVESTORS LP | 77.3K -29.4K (-27.6%) | 415.0K +41.6K (+11.2%) | 0.06% -0.021 pp | 0.03% +0.005 pp | USD3.50 +53.4% | 2 qtrs — |
| 78 | METLIFE INVESTMENT MANAGEMENT, LLC | 74.0K +15.6K (+26.8%) | 397.3K +193.1K (+94.5%) | 0.05% +0.011 pp | 0.00% +0.001 pp | USD2.90 +85.2% | 11 qtrs — |
| 79 | PRICE T ROWE ASSOCIATES INC /MD/ | 70.5K +13.9K (+24.6%) | 379.0K +180.0K (+90.5%) | 0.05% +0.010 pp | 0.00% +0.000 pp | USD2.99 +79.6% | 11 qtrs — |
| 80 | JANE STREET GROUP, LLC | 70.1K +38.4K (+121.2%) | 376.2K +265.4K (+239.3%) | 0.05% +0.028 pp | 0.00% +0.000 pp | USD3.77 +42.4% | 9 qtrs — |
| 81 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 69.6K +19.7K (+39.6%) | 373.7K +198.1K (+112.8%) | 0.05% +0.014 pp | 0.00% +0.000 pp | USD2.35 +128.5% | 7 qtrs — |
| 82 | FRANKLIN RESOURCES INC | 66.6K +66.6K (+100.0%) | 357.7K +357.7K (+100.0%) | 0.05% +0.048 pp | 0.00% +0.000 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 83 | INVESCO LTD. | 63.9K +3.2K (+5.3%) | 343.1K +130.9K (+61.6%) | 0.05% +0.002 pp | 0.00% +0.000 pp | USD2.74 +96.0% | 11 qtrs — |
| 84 | PERSISTENT ASSET PARTNERS LTD | 57.3K +57.3K (+100.0%) | 307.4K +307.4K (+100.0%) | 0.04% +0.041 pp | 0.14% +0.138 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 85 | PROFUND ADVISORS LLC | 57.2K +40.8K (+247.6%) | 307.4K +249.8K (+433.3%) | 0.04% +0.030 pp | 0.01% +0.008 pp | USD4.83 +11.2% | 2 qtrs — |
| 86 | GRAHAM CAPITAL MANAGEMENT, L.P. | 53.4K +53.4K (+100.0%) | 286.9K +286.9K (+100.0%) | 0.04% +0.039 pp | 0.01% +0.007 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 87 | VIRTUS INVESTMENT ADVISERS, INC. | 51.6K +51.6K (+100.0%) | 276.9K +276.9K (+100.0%) | 0.04% +0.037 pp | 0.08% +0.075 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 88 | D. E. SHAW & CO., INC. | 51.5K +51.5K (+100.0%) | 276.5K +276.5K (+100.0%) | 0.04% +0.037 pp | 0.00% +0.000 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 89 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 44.7K +24.8K (+124.2%) | 240.3K +170.4K (+243.9%) | 0.03% +0.018 pp | 0.00% +0.000 pp | USD3.68 +45.9% | 14 qtrs — |
| 90 | LPL FINANCIAL LLC | 44.5K +2.0K (+4.7%) | 238.8K +90.2K (+60.7%) | 0.03% +0.001 pp | 0.00% +0.000 pp | USD1.16 +362.9% | 7 qtrs — |
| 91 | AXQ CAPITAL, LP | 41.4K +41.4K (+100.0%) | 222.2K +222.2K (+100.0%) | 0.03% +0.030 pp | 0.05% +0.050 pp | USD5.37 +0.0% | 1 qtrs NEW |
| 92 | AMERICAN CENTURY COMPANIES INC | 40.4K +40.4K (+100.0%) | 217.0K +217.0K (+100.0%) | 0.03% +0.029 pp | 0.00% +0.000 pp | USD5.37 +0.0% | 4 qtrs — |
| 93 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 40.3K +7.2K (+21.6%) | 216.5K +100.5K (+86.6%) | 0.03% +0.005 pp | 0.00% +0.000 pp | USD2.47 +117.4% | 11 qtrs — |
| 94 | INTECH INVESTMENT MANAGEMENT LLC | 38.9K +— (+0.0%) | 209.1K +72.8K (+53.4%) | 0.03% +0.000 pp | 0.00% +0.001 pp | USD1.68 +219.6% | 6 qtrs — |
| 95 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 35.5K +7.2K (+25.3%) | 190.7K +91.5K (+92.3%) | 0.03% +0.005 pp | 0.00% +0.001 pp | USD2.55 +110.6% | 5 qtrs — |
| 96 | SIMPLICITY WEALTH,LLC | 33.9K -3.2K (-8.5%) | 181.9K +52.3K (+40.3%) | 0.02% -0.002 pp | 0.01% +0.003 pp | USD2.22 +141.9% | 4 qtrs — |
| 97 | NEW YORK STATE COMMON RETIREMENT FUND | 30.4K +— (+0.0%) | 163.3K +56.9K (+53.4%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.14 +71.0% | 11 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 77 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.71% | 406.7K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.22% | 458.2K | 0.50% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.15% | 53.2K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.15% | 15.98M | 0.35% |
| 5 | Vanguard U.S. Momentum Factor ETF VFMO | 0.13% | 2.19M | 0.13% |
| 6 | iShares Micro-Cap ETF IWC | 0.07% | 1.03M | 0.60% |
| 7 | Vanguard Global Momentum Factor ETF VMO.TO | 0.07% | 249.2K | 0.38% |
| 8 | Fidelity Enhanced Small Cap ETF FESM | 0.05% | 2.95M | 0.28% |
| 9 | Pacer WealthShield ETF PWS | 0.03% | 7.4K | 0.60% |
| 10 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 263.5K | 0.20% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
80.0K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+80,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Lerner Neil | Officer | P-Purchase | A | Common Stock | 15,000 | 1.89 | 28.4K | 397,500 | D | ↗ |
| 2026-04-29 | Anderman Jonathan | Officer | P-Purchase | A | Common Stock | 25,000 | 1.89 | 47.3K | 196,000 | D | ↗ |
| 2026-02-08 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 36,687 | 6.52 | 239.2K | 6,603,336 | D | ↗ |
| 2026-01-09 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 46,777 | 5.35 | 250.3K | 6,640,023 | D | ↗ |
| 2026-01-02 | Sirard Cynthia | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-02 | Shin Barry | Officer | A-Award | A | Stock Option (Right to Buy) | 670,000 | 5.17 | 3.46M | 670,000 | D | ↗ |
| 2026-01-02 | Schuetz Thomas J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 2,000,000 | 5.17 | 10.34M | 2,000,000 | D | ↗ |
| 2026-01-02 | Prasad Arjun | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-02 | Lerner Neil | Officer | A-Award | A | Stock Option (Right to Buy) | 435,000 | 5.17 | 2.25M | 435,000 | D | ↗ |
| 2026-01-02 | LINDAHL RICHARD S | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 5.17 | 465.3K | 90,000 | D | ↗ |
| 2026-01-02 | GRAY MARY ANN | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 5.17 | 465.3K | 90,000 | D | ↗ |
| 2026-01-02 | GORDON CARL L | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 5.17 | 465.3K | 90,000 | D | ↗ |
| 2026-01-02 | Ferneau Philip | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 5.17 | 465.3K | 90,000 | D | ↗ |
| 2026-01-02 | Chiniara Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 5.17 | 465.3K | 90,000 | D | ↗ |
| 2026-01-02 | Boylan James P | Director | A-Award | A | Stock Option (Right to Buy) | 90,000 | 5.17 | 465.3K | 90,000 | D | ↗ |
| 2026-01-02 | Anderman Jonathan | Officer | A-Award | A | Common Stock | 150,000 | 5.17 | 775.5K | 171,000 | D | ↗ |
| 2025-11-16 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 44,025 | 4.83 | 212.6K | 6,436,800 | D | ↗ |
| 2025-05-27 | Schuetz Thomas J. | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 2.11 | 21.1K | 6,480,825 | D | ↗ |
| 2025-04-09 | ORBIMED ADVISORS LLC | Director / 10% Owner | S-Sale | D | Common Stock | 3,571,428 | 1.59 | 5.68M | 0 | I | ↗ |
| 2025-04-09 | GORDON CARL L | Director / 10% Owner | S-Sale | D | Common Stock | 3,571,428 | 1.59 | 5.68M | 0 | I | ↗ |
| 2025-04-07 | Lerner Neil | Officer | P-Purchase | A | Common Stock | 20,000 | 1.42 | 28.4K | 320,000 | D | ↗ |
| 2025-04-07 | Anderman Jonathan | Officer | P-Purchase | A | Common Stock | 20,000 | 1.54 | 30.8K | 21,000 | D | ↗ |
| 2025-02-11 | Shin Barry | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 3.65 | 912.5K | 250,000 | D | ↗ |
| 2025-02-11 | Schuetz Thomas J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,500,000 | 3.65 | 5.48M | 1,500,000 | D | ↗ |
| 2025-02-11 | Lerner Neil | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 3.65 | 730.0K | 200,000 | D | ↗ |
| 2025-02-11 | LINDAHL RICHARD S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.65 | 146.0K | 40,000 | D | ↗ |
| 2025-02-11 | GRAY MARY ANN | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.65 | 146.0K | 40,000 | D | ↗ |
| 2025-02-11 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.65 | 146.0K | 40,000 | D | ↗ |
| 2025-02-11 | Ferneau Philip | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.65 | 146.0K | 40,000 | D | ↗ |
| 2025-02-11 | Chiniara Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.65 | 146.0K | 40,000 | D | ↗ |
| 2025-02-11 | Boylan James P | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.65 | 146.0K | 40,000 | D | ↗ |
| 2025-02-11 | Anderman Jonathan | Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 3.65 | 1.02M | 280,000 | D | ↗ |
| 2025-02-08 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 41,687 | 3.50 | 145.9K | 6,470,825 | D | ↗ |
| 2025-01-09 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 58,054 | 1.86 | 108.0K | 6,512,512 | D | ↗ |
| 2024-12-09 | Shin Barry | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-09 | Lerner Neil | Officer | — | — | Stock Option (right to buy) | 90,000 | 5.00 | 450.0K | 0 | D | ↗ |
| 2024-08-13 | Anderman Jonathan | Officer | A-Award | A | Stock Option (Right to Buy) | 300,000 | 1.20 | 360.0K | 300,000 | — | ↗ |
| 2024-08-01 | Anderman Jonathan | Officer | — | D | Stock Option (right to buy) | 50,000 | 2.40 | 120.0K | 0 | — | ↗ |
| 2024-03-08 | Boylan James P | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.96 | 78.4K | 40,000 | — | ↗ |
| 2024-02-09 | LINDAHL RICHARD S | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.57 | 62.8K | 40,000 | — | ↗ |
| 2024-02-09 | GRAY MARY ANN | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.57 | 62.8K | 40,000 | — | ↗ |
| 2024-02-09 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.57 | 62.8K | 40,000 | — | ↗ |
| 2024-02-09 | Ferneau Philip | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.57 | 62.8K | 40,000 | — | ↗ |
| 2024-02-09 | Chiniara Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.57 | 62.8K | 40,000 | — | ↗ |
| 2024-02-08 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 44,782 | 1.45 | 64.9K | 6,570,566 | — | ↗ |
| 2024-02-08 | Bisker-Leib Vered | Director / Officer | F-InKind | D | Common Stock | 49,198 | 1.45 | 71.3K | 3,124,426 | — | ↗ |
| 2024-01-09 | Schuetz Thomas J. | Director / Officer | A-Award | A | Common Stock | 637,500 | 1.93 | 1.23M | 6,615,348 | — | ↗ |
| 2024-01-09 | Bisker-Leib Vered | Director / Officer | A-Award | A | Common Stock | 1,753,125 | 1.93 | 3.38M | 3,173,624 | — | ↗ |
| 2023-11-17 | Schuetz Thomas J. | Director / Officer | F-InKind | D | Common Stock | 44,025 | 1.50 | 66.0K | 5,977,848 | — | ↗ |
| 2023-11-17 | Bisker-Leib Vered | Officer | F-InKind | D | Common Stock | 64,415 | 1.50 | 96.6K | 1,420,499 | — | ↗ |
| 2023-04-21 | LINDAHL RICHARD S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-03-10 | Schuetz Thomas J. | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 3.37 | 33.7K | 6,021,873 | — | ↗ |
| 2023-02-27 | Schuetz Thomas J. | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 3.98 | 79.6K | 6,011,873 | — | ↗ |
| 2023-02-15 | Schuetz Thomas J. | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 3.86 | 77.2K | 5,991,873 | — | ↗ |
| 2023-02-08 | WURZER DAVID M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-02-08 | Schuetz Thomas J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 3.93 | 2.75M | 700,000 | — | ↗ |
| 2023-02-08 | GRAY MARY ANN | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.93 | 157.2K | 40,000 | — | ↗ |
| 2023-02-08 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 60,000 | 3.93 | 235.8K | 60,000 | — | ↗ |
| 2023-02-08 | Ferneau Philip | Director | A-Award | A | Stock Option (Right to Buy) | 50,000 | 3.93 | 196.5K | 50,000 | — | ↗ |
| 2023-02-08 | Chiniara Ellen | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.93 | 157.2K | 40,000 | — | ↗ |
| 2023-02-08 | Bisker-Leib Vered | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 3.93 | 2.36M | 600,000 | — | ↗ |
| 2023-01-31 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,000 | 4.05 | 81.0K | 5,471,873 | — | ↗ |
| 2023-01-24 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,000 | 4.19 | 83.8K | 5,451,873 | — | ↗ |
| 2022-11-25 | Bisker-Leib Vered | Officer | S-Sale | D | Common Stock | 2 | 4.36 | 8.72 | 1,060,414 | — | ↗ |
| 2022-11-23 | Bisker-Leib Vered | Officer | S-Sale | D | Common Stock | 9,569 | 4.30 | 41.1K | 1,060,416 | — | ↗ |
| 2022-11-22 | Bisker-Leib Vered | Officer | S-Sale | D | Common Stock | 14,929 | 4.19 | 62.6K | 1,069,985 | — | ↗ |
| 2022-11-08 | ORBIMED ADVISORS LLC | Director | P-Purchase | A | Common Stock | 402,000 | 3.21 | 1.29M | 15,219,994 | — | ↗ |
| 2022-11-08 | GORDON CARL L | Director | P-Purchase | A | Common Stock | 402,000 | 3.21 | 1.29M | 15,219,994 | — | ↗ |
| 2022-11-04 | Boylan James P | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-09-07 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 15,000 | 3.03 | 45.5K | 5,406,873 | — | ↗ |
| 2022-09-01 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 15,000 | 2.83 | 42.5K | 5,391,873 | — | ↗ |
| 2022-08-17 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 15,000 | 3.05 | 45.8K | 5,376,873 | — | ↗ |
| 2022-08-10 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 15,000 | 2.64 | 39.6K | 5,361,873 | — | ↗ |
| 2022-08-01 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 15,000 | 2.58 | 38.7K | 5,346,873 | — | ↗ |
| 2022-06-21 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,000 | 2.80 | 56.0K | 5,331,873 | — | ↗ |
| 2022-06-16 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,000 | 2.34 | 46.8K | 5,311,873 | — | ↗ |
| 2022-06-13 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 30,000 | 2.29 | 68.7K | 5,291,873 | — | ↗ |
| 2022-06-06 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 30,000 | 2.83 | 84.9K | 5,261,873 | — | ↗ |
| 2022-06-01 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,000 | 3.03 | 60.6K | 5,231,873 | — | ↗ |
| 2022-05-26 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,000 | 3.04 | 60.8K | 5,211,873 | — | ↗ |
| 2022-05-23 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 18,355 | 2.72 | 49.9K | 5,191,873 | — | ↗ |
| 2022-05-17 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 20,215 | 2.47 | 49.9K | 5,173,518 | — | ↗ |
| 2022-05-13 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 30,722 | 2.49 | 76.5K | 14,817,994 | — | ↗ |
| 2022-05-12 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 97,094 | 2.35 | 228.2K | 14,787,272 | — | ↗ |
| 2022-05-12 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 97,094 | 2.35 | 228.2K | 14,787,272 | — | ↗ |
| 2022-05-11 | OrbiMed Genesis GP LLC | Director | P-Purchase | A | Common Stock | 64,700 | 1.79 | 115.8K | 14,690,178 | — | ↗ |
| 2022-05-11 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 64,700 | 1.79 | 115.8K | 14,690,178 | — | ↗ |
| 2022-05-11 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 64,700 | 1.79 | 115.8K | 14,690,178 | — | ↗ |
| 2022-05-10 | Schuetz Thomas J. | Officer | P-Purchase | A | Common Stock | 27,836 | 1.80 | 50.1K | 5,153,303 | — | ↗ |
| 2022-05-10 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 24,447 | 1.60 | 39.1K | 14,625,478 | — | ↗ |
| 2022-05-09 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 90,712 | 1.56 | 141.5K | 14,601,031 | — | ↗ |
| 2022-05-09 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 90,712 | 1.56 | 141.5K | 14,601,031 | — | ↗ |
| 2022-05-06 | OrbiMed Genesis GP LLC | Director | P-Purchase | A | Common Stock | 24,447 | 1.60 | 39.1K | 14,625,478 | — | ↗ |
| 2022-05-06 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 10,200 | 1.63 | 16.6K | 14,510,319 | — | ↗ |
| 2022-05-06 | GORDON CARL L | Director | P-Purchase | A | Common Stock | 24,447 | 1.60 | 39.1K | 14,625,478 | — | ↗ |
| 2022-04-26 | GRAY MARY ANN | Director | A-Award | A | Stock Option (Right to Buy) | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-04-26 | Chiniara Ellen | Director | — | D | Common Stock, $.0001 Par Value | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-18 | Schuetz Thomas J. | Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 2.40 | 1.68M | 700,000 | — | ↗ |
| 2022-02-18 | SQUINTO STEPHEN P | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.40 | 72.0K | 30,000 | — | ↗ |
| 2022-02-18 | Kaplan Brett | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.40 | 72.0K | 30,000 | — | ↗ |
| 2022-02-18 | Kalled Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 2.40 | 144.0K | 60,000 | — | ↗ |
| 2022-02-18 | GORDON CARL L | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.40 | 72.0K | 30,000 | — | ↗ |
| 2022-02-18 | Ferneau Philip | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.40 | 72.0K | 30,000 | — | ↗ |
| 2022-02-18 | Bisker-Leib Vered | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 2.40 | 1.20M | 500,000 | — | ↗ |
| 2022-02-17 | Schuetz Thomas J. | Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 2.52 | 1.76M | 700,000 | — | ↗ |
| 2022-02-17 | Kalled Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 2.52 | 151.2K | 60,000 | — | ↗ |
| 2022-02-17 | Bisker-Leib Vered | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 2.52 | 1.26M | 500,000 | — | ↗ |
| 2021-11-16 | Schuetz Thomas J. | Director / Officer | A-Award | A | Common Stock | 600,000 | 0.00 | — | 5,125,467 | — | ↗ |
| 2021-11-16 | Bisker-Leib Vered | Officer | A-Award | A | Common Stock | 600,000 | 0.00 | — | 1,113,401 | — | ↗ |
| 2021-11-04 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 1,785,715 | 3.50 | 6.25M | 14,500,119 | — | ↗ |
| 2021-11-04 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 1,785,715 | 3.50 | 6.25M | 14,500,119 | — | ↗ |
| 2021-06-25 | Toledano Miranda Jayne | Director | J-Other | A | Common Stock, $.0001 Par Value | 1,791,549 | 5.85 | 10.48M | 1,791,549 | — | ↗ |
| 2021-05-03 | Kalled Susan | Officer | A-Award | A | Stock Option (Right to Buy) | 260,000 | 7.00 | 1.82M | 260,000 | — | ↗ |
| 2021-02-09 | Schuetz Thomas J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 700,000 | 5.00 | 3.50M | 700,000 | — | ↗ |
| 2021-02-09 | Bisker-Leib Vered | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 5.00 | 2.00M | 400,000 | — | ↗ |
| 2020-12-22 | Schuetz Thomas J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 5.00 | 1.25M | 250,000 | — | ↗ |
| 2020-09-10 | Kaplan Brett | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 5.00 | 300.0K | 60,000 | — | ↗ |
| 2020-08-06 | Schuetz Thomas J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 5.00 | 2.50M | 500,000 | — | ↗ |
| 2020-08-06 | SQUINTO STEPHEN P | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 5.00 | 150.0K | 30,000 | — | ↗ |
| 2020-08-06 | Bisker-Leib Vered | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 5.00 | 3.00M | 600,000 | — | ↗ |
| 2020-06-19 | Sunderland Julie | Director | P-Purchase | A | Common Stock | 289,118 | 5.00 | 1.45M | 2,502,025 | — | ↗ |
| 2020-06-19 | Schuetz Thomas J. | Director / Officer | P-Purchase | A | Common Stock | 97,431 | 5.00 | 487.2K | 4,525,467 | — | ↗ |
| 2020-06-19 | ORBIMED ADVISORS LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 1,455,132 | 5.00 | 7.28M | 12,714,404 | — | ↗ |
| 2020-06-19 | GORDON CARL L | Director / 10% Owner | P-Purchase | A | Common Stock | 1,455,132 | 5.00 | 7.28M | 12,714,404 | — | ↗ |
| 2020-06-19 | Ferneau Philip | Director | P-Purchase | A | Common Stock | 64,066 | 5.00 | 320.3K | 2,348,976 | — | ↗ |
| 2020-06-17 | Sunderland Julie | Director | — | I | Common Stock | 0 | 0.00 | — | 2,212,907 | — | ↗ |
| 2020-06-17 | Schuetz Thomas J. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 4,428,036 | — | ↗ |
| 2020-06-17 | SQUINTO STEPHEN P | Director | — | D | Common Stock | 0 | 0.00 | — | 34,540 | — | ↗ |
| 2020-06-17 | ORBIMED ADVISORS LLC | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 11,259,272 | — | ↗ |
| 2020-06-17 | GORDON CARL L | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 11,259,272 | — | ↗ |
| 2020-06-17 | Ferneau Philip | Director | — | I | Common Stock | 0 | 0.00 | — | 150,280 | — | ↗ |
| 2020-06-17 | Bisker-Leib Vered | Officer | — | D | Common Stock | 0 | 0.00 | — | 513,401 | — | ↗ |
| 2020-06-17 | ANDERSON ERRIK | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 383,642 | — | ↗ |
| 2018-07-29 | Tompkins Mark N. | Director / 10% Owner | — | D | Common Stock, par value $0.0001 | 0 | 0.00 | — | 4,750,000 | — | ↗ |
| 2018-07-29 | Jacobs Ian Seth | Director / Officer | — | D | Common Stock, par value $0.0001 | 0 | 0.00 | — | 250,000 | — | ↗ |
| 2006-02-24 | YOUNGSTROM SCOTT P | Officer | D-Return | D | Employee Stock Option (Right to Buy) | 160,000 | 3.70 | 592.0K | 0 | — | ↗ |
| 2006-02-24 | SMITH JACK A | Director | D-Return | D | Director Stock Option | 15,000 | 8.30 | 124.5K | 0 | — | ↗ |
| 2006-02-24 | GLADNEY DAN W | Director / Officer | D-Return | D | Employee Stock Option (Right to Buy) | 250,000 | 3.58 | 894.8K | 0 | — | ↗ |
| 2006-02-21 | YOUNGSTROM SCOTT P | Officer | M-Exempt | A | Common Stock | 40,000 | 3.70 | 148.0K | 56,621 | — | ↗ |
| 2006-02-13 | SMITH JACK A | Director | M-Exempt | A | Common Stock | 20,000 | 5.18 | 103.6K | 22,000 | — | ↗ |
| 2005-12-19 | GLADNEY DAN W | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 19,000 | 3.58 | 68.0K | 231,000 | — | ↗ |
| 2005-05-12 | GLADNEY DAN W | Director / Officer | P-Purchase | A | Common Stock | 1,864 | 3.84 | 7.2K | 25,745 | — | ↗ |
| 2005-05-11 | GLADNEY DAN W | Director / Officer | P-Purchase | A | Common Stock | 3,136 | 3.70 | 11.6K | 23,881 | — | ↗ |
| 2005-05-10 | YOUNGSTROM SCOTT P | Officer | P-Purchase | A | Common Stock | 4,000 | 3.48 | 13.9K | 16,621 | — | ↗ |
| 2004-11-15 | SMITH JACK A | Director | P-Purchase | A | Common Stock | 2,000 | 4.90 | 9.8K | 2,000 | — | ↗ |
| 2004-11-11 | SMITH JACK A | Director | M-Exempt | A | Director Stock Option | 20,000 | 5.18 | 103.6K | 20,000 | — | ↗ |
| 2004-06-02 | YOUNGSTROM SCOTT P | Officer | A-Award | A | Common Stock | 2,500 | 0.00 | — | 7,881 | — | ↗ |
| 2004-06-02 | GLADNEY DAN W | Director / Officer | A-Award | A | Common Stock | 10,000 | 0.00 | — | 16,414 | — | ↗ |
| 2004-03-29 | SMITH JACK A | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
138.29M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Thomas J. Schuetz, MD., Ph.D. Chief Executive Officer | 630.0K | 381.2K | — | 4.07M | — | 21.0K | 5.10M | 79.75% | ↗ |
| 2 | 2025 | Jonathan Anderman General Counsel and Corporate Secretary | 450.0K | 198.0K | — | 758.8K | — | — | 1.43M | 53.14% | ↗ |
| 3 | 2025 | Barry Shin Chief Financial Officer | 480.0K | 216.0K | — | 677.5K | — | 21.0K | 1.39M | 48.58% | ↗ |
| 4 | 2024 | Vered Bisker-Leib, Ph.D., MBA Formerly Chief Executive Officer | 600.0K | — | 3.38M | 2.39M | — | 63.5K | 6.43M | 89.69% | ↗ |
| 5 | 2024 | Thomas J. Schuetz, M.D., Ph.D. Chief Executive Officer | 575.0K | 400.0K | 1.23M | 867.9K | — | 19.8K | 3.09M | 67.84% | ↗ |
| 6 | 2024 | Thomas J. Schuetz, MD., Ph.D. Chief Executive Officer | 575.0K | 400.0K | 1.23M | 867.9K | — | 19.8K | 3.09M | 67.84% | ↗ |
| 7 | 2024 | Barry Shin Chief Financial Officer | 296.9K | 50.0K | 660.0K | 481.3K | — | — | 1.22M | 93.47% | ↗ |
| 8 | 2024 | Jonathan Anderman General Counsel and Corporate Secretary | 326.8K | 195.0K | — | 352.0K | — | 19.8K | 893.6K | 39.39% | ↗ |
| 9 | 2023 | Thomas J. Schuetz, M.D., Ph.D. Chief Executive Officer | 575.0K | 244.4K | 1.97M | 2.07M | — | 16.5K | 4.87M | 82.85% | ↗ |
| 10 | 2023 | Thomas J. Schuetz, M.D., Ph.D. President of Research & Development (formerly CEO) | 575.0K | 244.4K | 1.97M | 2.07M | — | 16.5K | 4.87M | 82.85% | ↗ |
| 11 | 2023 | Vered Bisker-Leib, Ph.D., MBA Formerly Chief Executive Officer | 500.0K | 202.5K | 1.57M | 1.78M | — | 16.5K | 4.07M | 82.32% | ↗ |
| 12 | 2023 | Vered Bisker-Leib, Ph.D., MBA Chief Executive Officer (formerly President and COO) | 500.0K | 202.5K | 1.57M | 1.78M | — | 16.5K | 4.07M | 82.32% | ↗ |
| 13 | 2023 | Jonathan Anderman General Counsel and Corporate Secretary | 338.0K | 116.6K | — | 236.8K | — | 16.5K | 707.9K | 33.45% | ↗ |
| 14 | 2022 | Thomas J. Schuetz, M.D., Ph.D. President of Research & Development (formerly CEO) | 550.0K | 275.0K | — | 1.29M | — | 4.6K | 2.12M | 60.78% | ↗ |
| 15 | 2022 | Thomas J. Schuetz, M.D., Ph.D. Chief Executive Officer | 550.0K | 275.0K | — | 1.29M | — | 4.6K | 2.11M | 60.91% | ↗ |
| 16 | 2022 | Vered Bisker-Leib, Ph.D., MBA Chief Executive Officer (formerly President and COO) | 475.0K | 320.0K | — | 918.3K | — | 11.4K | 1.72M | 53.24% | ↗ |
| 17 | 2022 | Vered Bisker-Leib, Ph.D., MBA President and Chief Operating Officer | 475.0K | 320.0K | — | 918.3K | — | 11.4K | 1.71M | 53.60% | ↗ |
| 18 | 2022 | Susan Kalled, Ph.D. Chief Scientific Officer | 297.5K | — | — | 110.2K | — | 54.3K | 62.0K | 177.65% | ↗ |
| 19 | 2021 | Thomas J. Schuetz, M.D., Ph.D. Chief Executive Officer | 4.0K | 450.0K | 2.30M | 2.51M | — | — | 5.26M | 91.37% | ↗ |
| 20 | 2021 | Vered Bisker-Leib, Ph.D., MBA President and Chief Operating Officer | 400.0K | 320.0K | 2.30M | 1.43M | — | 16.0K | 4.45M | 83.82% | ↗ |
| 21 | 2021 | Susan Kalled, Ph.D. Chief Scientific Officer | 220.0K | 115.5K | — | 1.45M | — | — | 1.78M | 81.17% | ↗ |
| 22 | 2020 | Vered Bisker-Leib, Ph.D., MBA President and Chief Operating Officer | 360.0K | 160.0K | — | 2.05M | — | — | 2.57M | 79.78% | ↗ |
| 23 | 2020 | Thomas J. Schuetz, M.D., Ph.D. Chief Executive Officer | 4.0K | — | — | 2.55M | — | — | 2.56M | 99.84% | ↗ |
| 24 | 2019 | Thomas J. Schuetz, M.D., Ph.D. Chief Executive Officer | 400.0K | — | 973.8K | — | — | — | 1.37M | 70.88% | ↗ |
| 25 | 2019 | Vered Bisker-Leib, Ph.D., MBA President and Chief Operating Officer | 325.0K | 160.9K | 569.2K | — | — | — | 1.06M | 53.95% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas J. Schuetz | Chief Executive Officer & Vice Chairman | 1M | — |
| Barry Shin | Chief Financial Officer | 717.0K | male |
| Jonathan Anderman | Senior Vice President, General Counsel & Corporate Secretary | 648.0K | male |
| Bing Gong | Chief Scientific Officer | 445.5K | male |
| Karin Herrera | Senior Vice President & Head of Clinical Operations | — | female |
| Neil L. Lerner | Senior Vice President & Chief Accounting Officer | — | male |
| James Kranz | Vice President and Head of Chemistry Manufacturing & Controls | — | — |
| Arjun Prasad | Chief Commercial Officer | — | male |
| Cynthia A. Sirard | Chief Medical Officer | — | — |
| Anna Gifford | Senior Manager of Communications & Chief of Staff | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CMPX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
